Our study suggests that dynamic evaluation of genomic profile, especially oncogenic drivers such as EGFR mutational status, at cancer recurrence or relapse (or second primary) is warranted to tailor subsequent individualized therapy. The gene discussed is EGFR; the disease is cancer.